Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Hong

Cardiovascular Disease Los Angeles, CA Medical Doctor

NPI 1578668703 CMS profile 344323

520 S Virgil Ave, Suite 501, Los Angeles, CA 90020

Open in the dashboard

General payments

$18,577

591 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Hong of Los Angeles, CA is reported in the CMS Open Payments database as having received $18,577 across 591 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,972 74
2024 General $3,985 108
2023 General $2,770 89
2022 General $1,951 99
2021 General $2,475 113
2020 General $1,217 43
2019 General $4,206 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Hong
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Gregory Hong were reported at $1,972. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Gregory Hong Cardiovascular Disease median Middle half National median
2019 $4,206 $450 $127–$1,392 $163
2020 $1,217 $242 $77–$751 $114
2021 $2,475 $335 $101–$1,037 $132
2022 $1,951 $395 $121–$1,211 $149
2023 $2,770 $443 $136–$1,283 $160
2024 $3,985 $450 $136–$1,323 $164
2025 $1,972 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,186 147 payments
  2. AstraZeneca Pharmaceuticals LP $1,863 52 payments
  3. Boston Scientific Corporation $1,626 10 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,530 54 payments
  5. Janssen Pharmaceuticals, Inc $1,126 48 payments
  6. Edwards Lifesciences Corporation $1,115 20 payments
  7. Merck Sharp & Dohme Corporation $1,098 32 payments
  8. E.R. Squibb & Sons, L.L.C. $1,041 43 payments
  9. Medtronic Vascular, Inc. $991 7 payments
  10. Amgen Inc. $962 47 payments
  11. Other $5,038 131 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,091 577 payments
  2. Travel and Lodging $2,154 6 payments
  3. Education $332 8 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,350 45 payments
  2. ANGIOJET $1,331 4 payments
  3. VERQUVO $1,262 36 payments
  4. ENTRESTO $1,148 92 payments
  5. XARELTO $1,142 48 payments
  6. MICRA $947 6 payments
  7. JARDIANCE $930 34 payments
  8. SAPIEN 3 Ultra RESILIA $862 14 payments
  9. Repatha $848 42 payments
  10. LEQVIO $784 37 payments
  11. Other $9,606 298 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

5,694

Median for Cardiology: 2,533

Drug cost

$1,802,369

Median for Cardiology: $485,213

Branded share of claims

44.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 305 $308,099
Jardiance Empagliflozin Brand 297 $289,422
Ozempic Semaglutide Brand 265 $283,246
Eliquis Apixaban Brand 250 $225,686
Xarelto Rivaroxaban Brand 251 $208,762
Farxiga Dapagliflozin Propanediol Brand 201 $171,359
Repatha Sureclick Evolocumab Brand 90 $65,443
Verquvo Vericiguat Brand 36 $48,265
Multaq Dronedarone Hcl Brand 39 $37,391
Vascepa Icosapent Ethyl Brand 42 $20,072

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$230,522

Of which drugs: $350

Medicare patients

287

Average age 76

Services billed

3,788

164 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 67%
Arthritis 45%
Chronic kidney disease 41%
Ischemic heart disease 36%
Heart failure 30%
Atrial fibrillation 25%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dobutamine hydrochloride, per 250 mg J1250 Office 50 50 $350

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $593
  • Lilly USA, LLC $128
$721 297 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $421
$421 201 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $312
$312 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $237
$237 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $196
  • Janssen Biotech, Inc. $29
$225 251 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

591 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record